Role of KATP channels in the regulation of rat dura and pia artery diameter

Cephalalgia

Volumn 25, Issue 4, 2005, Pages 249-260

  Gozalov, Aydin ^a,c   Petersen, K A ^a   Mortensen, C ^a   Jansen Olesen, I ^a   Klaerke, D ^b   Olesen, J ^a  

^a GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Dural and pial arteries; Glibenclamide; KATP channels; Levcromakalim; Pinacidil

Indexed keywords

ADENOSINE TRIPHOSPHATE; GLIBENCLAMIDE; LEMAKALIM; PINACIDIL; POTASSIUM CHANNEL; CROMAKALIM; VASODILATOR AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERY DIAMETER; ARTERY DILATATION; ARTICLE; CHANNEL GATING; CONTROLLED STUDY; DRUG INFUSION; DURA MATER; IN VITRO STUDY; IN VIVO STUDY; MALE; MEAN ARTERIAL PRESSURE; MIDDLE CEREBRAL ARTERY; NONHUMAN; PIA ARTERY; PROTEIN FUNCTION; RAT; ANIMAL; ARTERY; CYTOLOGY; DRUG EFFECT; PHYSIOLOGY; PIA MATER; SPRAGUE DAWLEY RAT; VASCULARIZATION; VASODILATATION;

ANIMALS; ARTERIES; CROMAKALIM; DURA MATER; GLYBURIDE; MALE; PIA MATER; PINACIDIL; POTASSIUM CHANNELS; RATS; RATS, SPRAGUE-DAWLEY; VASODILATION; VASODILATOR AGENTS;

EID: 15944400697     PISSN: 03331024     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-2982.2004.00848.x     Document Type: Article

References (42)

1. Ophoff RA, Terwindt GM, Vergouwe MN, van Eijk R, Oefner PJ, Hoffman SM et al. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell 1996; 87:543-52.
2. Terwindt GM, Ophoff RA, van Eijk R, Vergouwe MN, Haan J, Frants RR et al. Involvement of the CACNA1A gene containing region on 19p13 in migraine with and without aura. Neurology 2001; 56:1028-32.
3. Goadsby PJ, Lipton RB, Ferrari MD. Migraine - current understanding and treatment. N Engl J Med 2002; 346:257-70.
4. Ray BS, Wolff HG. Experimental studies on headache: pain sensitive structures of the head and their significance in headache. Arch Surg 1940; 41:813-56.
5. Faraci FM, Heistad DD. Regulation of the cerebral circulation: role of endothelium and potassium channels. Physiol Rev 1998; 78:53-97.
6. Nelson MT, Quayle JM. Physiological roles and properties of potassium channels in arterial smooth muscle. Am J Physiol 1995; 268 (4 Part 1):C799-C822.
7. Williamson DJ, Hargreaves RJ, Hill RG, Shepheard SL. Sumatriptan inhibits neurogenic vasodilation of dural blood vessels in the anaesthetized rat - intravital microscope studies. Cephalalgia 1997; 17:525-31.
8. Quast U, Cook NS. In vitro and in vivo comparison of two K+ channel openers, diazoxide and cromakalim, and their inhibition by glibenclamide. J Pharmacol Exp Ther 1989; 250:261-71.
9. Schmid-Antomarchi H, de Weille J, Fosset M, Lazdunski M. The antidiabetic sulfonylurea glibenclamide is a potent blocker of the ATP-modulated K+ channel in insulin secreting cells. Biochem Biophys Res Commun 1987; 146:21-5.
10. Sturgess NC, Kozlowski RZ, Carrington CA, Hales CN, Ashford ML. Effects of sulphonylureas and diazoxide on insulin secretion and nucleotide-sensitive channels in an insulin-secreting cell line. Br J Pharmacol 1988; 95:83-94.
11. Gerrits RJ, Stein EA, Greene AS. Laser-Doppler flowmetry utilizing a thinned skull cranial window preparation and automated stimulation. Brain Res Brain Res Protoc 1998; 3:14-21.
12. Cook NS, Quast U, Hof RP, Baumlin Y, Pally C. Similarities in the mechanism of action of two new vasodilator drugs: pinacidil and BRL 34915. J Cardiovasc Pharmacol 1988; 11:90-9.
13. Nyborg NC, Baandrup U, Mikkelsen EO, Mulvany MJ. Active, passive and myogenic characteristics of isolated rat intramural coronary resistance arteries. Pflugers Arch 1987; 410:664-70.
14. Rosenblum WI, Wei EP, Kontos HA. Dimethylsulfoxide and ethanol, commonly used diluents, prevent dilation of pial arterioles by openers of K(ATP) ion channels. Eur J Pharmacol 2001; 430:101-6.
15. Wei EP, Kontos HA, Beckman JS. Antioxidants inhibit ATP-sensitive potassium channels in cerebral arterioles. Stroke 1998; 29:817-22.
16. Quayle JM, Nelson MT, Standen NB. ATP-sensitive and inwardly rectifying potassium channels in smooth muscle. Physiol Rev 1997; 77:1165-232.
17. Zhang H, Stockbridge N, Weir B, Vollrath B, Cook D. Vasodilatation of canine cerebral arteries by nicorandil, pinacidil and lemakalim. Gen Pharmacol 1992; 23:197-201.
18. Faraci FM, Heistad DD. Role of ATP-sensitive potassium channels in the basilar artery. Am J Physiol 1993; 264 (1 Part 2):H8-13.
19. Taguchi H, Heistad DD, Kitazono T, Faraci FM. ATP-sensitive K+ channels mediate dilatation of cerebral arterioles during hypoxia. Circ Res 1994; 74:1005-8.
20. Wahl M, Parsons AA, Schilling L. Dilating effect of perivascularly applied potassium channel openers cromakalim and pinacidil in rat and cat pial arteries in situ. Cardiovasc Res 1994; 28:1803-7.
21. Parsons AA, Ksoll E, Mackert JR, Schilling L, Wahl M. Comparison of cromakalim-induced relaxation of potassium precontracted rabbit, cat, and rat isolated cerebral arteries. Naunyn Schmiedebergs Arch Pharmacol 1991; 343:384-92.
22. Sturgess NC, Ashford ML, Cook DL, Hales CN. The sulphonylurea receptor may be an ATP-sensitive potassium channel. Lancet 1985; 2:474-5.
23. Dirnagl U, Kaplan B, Jacewicz M, Pulsinelli W. Continuous measurement of cerebral cortical blood flow by laser-Doppler flowmetry in a rat stroke model. J Cereb Blood Flow Metab 1989; 9:589-96.
24. Fabricius M, Lauritzen M. Laser-Doppler evaluation of rat brain microcirculation: comparison with the [14C]-iodoantipyrine method suggests discordance during cerebral blood flow increases. J Cereb Blood Flow Metab 1996; 16:156-61.
25. Williamson DJ, Hargreaves RJ, Hill RG, Shepheard SL. Intravital microscope studies on the effects of neurokinin agonists and calcitonin gene-related peptide on dural vessel diameter in the anaesthetized rat. Cephalalgia 1997; 17:518-24.
26. Gustafson C, Aronsen KF, Rosberg B. Circulatory effects of haemorrhage during sodium nitroprusside induced hypotension. A study in the rat. Acta Anaesthesiol Scand 1985; 29:502-7.
27. Navari RM, Wei EP, Kontos HA, Patterson JL Jr. Comparison of the open skull and cranial window preparations in the study of the cerebral microcirculation. Microvasc Res 1978; 16:304-15.
28. Armstead WM. Hypotension dilates pial arteries by KATP and kca channel activation. Brain Res 1999; 816: 158-64.
29. Graham JR, Wolff HG. Mechanism of migraine headache and action of ergotamine tartrate. Arch Neurol Psychiatry 1938; 39:737-63.
30. Humphrey PP, Feniuk W. Mode of action of the anti-migraine drug sumatriptan. Trends Pharmacol Sci 1991; 12:444-6.
31. Moskowitz MA. Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine. Trends Pharmacol Sci 1992; 13:307-11.
32. Iversen HK, Olesen J, Tfelt-Hansen P. Intravenous nitroglycerin as an experimental model of vascular headache. Basic characteristics. Pain 1989; 38:17-24.
33. Iversen HK, Olesen J. Headache induced by a nitric oxide donor (nitroglycerin) responds to sumatriptan. A human model for development of migraine drugs. Cephalalgia 1996; 16:412-8.
34. Lassen LH, Thomsen LL, Kruuse C, Iversen HK, Olesen J. Histamine-1 receptor blockade does not prevent nitroglycerin induced migraine. Support for the NO-hypothesis of migraine. Eur J Clin Pharmacol 1996; 49:335-9.
35. Tfelt-Hansen P, Brand J, Dano P, Doenicke A, Findley LJ, Iversen HK et al. Early clinical experience with subcutaneous GR43175 in acute migraine: an overview. Cephalalgia 1989; 9 (Suppl. 9):73-7.
36. Frampton J, Buckley MM, Fitton A. Nicorandil. A review of its pharmacology and therapeutic efficacy in angina pectoris. Drugs 1992; 44:625-55.
37. Friedel HA, Brogden RN. Pinacidil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of hypertension. Drugs 1990; 39:929-67.
38. Goldberg MR. Clinical pharmacology of pinacidil, a prototype for drugs that affect potassium channels. J Cardiovasc Pharmacol 1988; 12 (Suppl. 2):S41-S47.
39. Markham A, Plosker GL, Goa KL. Nicorandil. An updated review of its use in ischaemic heart disease with emphasis on its cardioprotective effects. Drugs 2000; 60:955-74.
40. Roland E. Safety profile of an anti-anginal agent with potassium channel opening activity: an overview. Eur Heart J 1993; 14 (Suppl. B):48-52.
41. Suzuki S, Yano K, Kusano S, Hashimoto T. Antihypertensive effect of levcromakalim in patients with essential hypertension. Study by 24-h ambulatory blood pressure monitoring. Arzneimittelforschung 1995; 45:859-64.
42. Why HJ, Richardson PJ. A potassium channel opener as monotherapy in chronic stable angina pectoris: comparison with placebo. Eur Heart J 1993; 14 (Suppl. B):25-9.